Should Income Investors Buy This Big Pharma Stock?
Amid the start of the COVID-19 pandemic, big pharma companies like (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible mobilization on the part of Pfizer and this public health emergency resulted in massive business opportunities for the company.
The Comirnaty COVID-19 vaccine co-owned with BioNTech became the best-selling pharmaceutical product of all time for a single year, topping $40 billion in revenue for 2022. And the anti-viral treatment Paxlovid wasn't far behind at $19 billion.
But now with the World Health Organization recently declaring an end to COVID-19 as a global health emergency, the real questions are as follows: Can Pfizer maintain its business momentum over the long run? And is the stock a buy for income investors? Let's look at Pfizer's fundamentals and valuation to decide.
Source Fool.com
Pfizer Inc. Stock
With 28 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a positive potential of 44.24% for Pfizer Inc. compared to the current price of 28.43 €.
